tebu-bio is a European company specialised in providing innovative reagents and laboratory services in Life Sciences

Need an answer now?

Give us a call

Leave a message, we'll get back to you

ADCC Screening Services

Quickly reveal the ADCC potential of your antibody

Antibody-dependent cell-mediated cytotoxicity (ADCC) is a major immune defense mechanism through which effector cells of the immune system (e.g. natural killer cells, macrophages, and neutrophils..), can recognize and eliminate unwanted cells such as tumour or virally infected cells (e.g. SARS-CoV-2).

In the current context where monoclonal antibodies with ADCC effects (Trastuzamab, Rituwximab..) are increasingly being validated by heath agencies for the treatment of specific diseases, assessing the capability of your molecule to recruit and activate immune cells to find and kill unwanted targets is a crucial step in the development of your therapeutic antibodies.

Assay Principle

Tebubio's in vitro assay uses two different engineered cell lines - Jurkat effector cells expressing Fc receptors and inducible firefly luciferase (Effector cells) developed by BPS Biosciences, and target cells expressing expressing specific disease marker 
(figure - right: Model developed for ADCC evaluation against SARS-CoV-2).

The effector cells contain a firefly luciferase reporter gene under the control of the NFAT response element. In addition, the cells constitutively express the human receptor FcγRIIIa, high affinity (V158) variant and Fcγ chain. Upon Fc receptor activation, NFAT-dependent signaling activates the expression of luciferase.

The target cells are co-cultured with Jurkat effector cells, in the presence or absence of a test antibody (Fig 2 : Control to remove aspecfic ADCC effect). If the test antibody displays ADCC-inducer activity, translates into the activation of luciferase expression that can be monitored using luminescent revelation reaction (Fig 3: ADCC capability validation on a SARS-CoV-2 model - Fig 4 : ADCC assay validation with anti cancer mAB gold standard: Trastazumab).


Figure 2 Figure 3 Figure 4

Benefit from an integrated solution to facilitate your research